8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.
2015 / Two-week dietary exchange trial
Researchers performed supervised 2-week food exchanges where African Americans consumed a high-fibre, low-fat African-style diet and rural Africans consumed a high-fat, low-fibre western-style diet. Compared with usual diets, the dietary switch led to reciprocal changes in mucosal biomarkers of cancer risk, microbiota, and the metabolome. In African Americans, these changes were highlighted by increased saccharolytic fermentation and butyrogenesis alongside suppressed secondary bile acid synthesis.
O'Keefe SJ, Li JV, Lahti L, et al. Nat Commun, 2015. PMID 25919227
2015 / Phase I trial
Thirty-six patients with rising prostate-specific antigen levels received escalating doses of white button mushroom powder in a phase I trial. No dose-limiting toxicities occurred, and the overall prostate-specific antigen response rate was 11%. Complete responses occurred in two patients receiving 8 and 14 g/d, with reductions to undetectable levels lasting 49 and 30 months.
Twardowski P, Kanaya N, Frankel P, et al. Cancer, 2015. PMID 25989179
2015 / Randomized, double-blind, placebo-controlled trial
In a randomized trial, 1,075 postmenopausal women took daily green tea extract containing 843 mg epigallocatechin-3-gallate or placebo for one year. Overall adverse event rates were similar between groups (75.6% vs. 72.8%). However, the extract group experienced more nausea (P < 0.001) and significantly more alanine aminotransferase elevations (6.7% vs. 0.7%, P < 0.001), including 1.3% with serious related events.
Dostal AM, Samavat H, Bedell S, et al. Food Chem Toxicol, 2015. PMID 26051348
2015 / Randomized crossover trial
In a randomized crossover trial, 23 healthy individuals consumed 300 g/d of cooked red meat alone (HRM) or with 40 g/d of butyrylated high-amylose maize starch (HRM+HAMSB) for 4 weeks each, separated by a 4-week washout. The HRM diet increased rectal O6MeG adducts by 21% relative to baseline (P < 0.01), but the addition of HAMSB prevented this increase. Epithelial proliferation increased with both diets compared to baseline, but was lower following HRM+HAMSB compared to HRM (P < 0.05). HRM+HAMSB also increased stool SCFA excretion by over 20% (P < 0.05) and altered fecal microbiota abundances.
Le Leu RK, Winter JM, Christophersen CT, et al. Br J Nutr, 2015. PMID 26084032
2015 / Experimental animal study and pilot clinical trial
Cycles of a fasting mimicking diet extended lifespan, stimulated stem cell regeneration upon re-feeding, reduced visceral fat, decreased cancer incidence, and improved cognitive performance in mice. In a pilot clinical trial, three cycles of the fasting mimicking diet decreased risk factors and biomarkers associated with aging, diabetes, cardiovascular disease, and cancer without causing major adverse effects.
Brandhorst S, Choi IY, Wei M, et al. Cell Metab, 2015. PMID 26094889
2015 / Randomized controlled trial
In a randomized trial with 183 men showing rising PSA levels after prostate cancer therapy, subjects received pomegranate extract (n=102), placebo (n=64), or juice (n=17). Median PSA doubling time increased across all groups: 11.1 to 15.6 months with placebo, 12.9 to 14.5 months with extract, and 12.7 to 20.3 months with juice, but differences between groups were not statistically significant (P>0.05).
Pantuck AJ, Pettaway CA, Dreicer R, et al. Prostate Cancer Prostatic Dis, 2015. PMID 26169045
2015 / Randomized crossover trial
A crossover trial randomized 22 healthy adults to consume approximately 50 g of palm dates or a control carbohydrate supplement daily for 21 days separated by a 14-day washout. Date intake did not alter short-chain fatty acids or selected bacterial groups. However, date intake significantly increased bowel movement frequency (P<0.01; n=21), reduced stool ammonia (P<0.05; n=21), and lowered fecal water genotoxicity compared to control (P<0.01; n=21).
Eid N, Osmanova H, Natchez C, et al. Br J Nutr, 2015. PMID 26428278
2015 / Randomized controlled trial
Thirteen women with HER2-negative stage II or III breast cancer receiving chemotherapy were randomized to fast for 24 hours before and after infusion or follow standard dietary guidelines. Seven days post-chemotherapy, mean erythrocyte counts (P = 0.007, 95% CI 0.106 to 0.638) and thrombocyte counts (P = 0.00007, 95% CI 38.7 to 104) were significantly higher in the fasting group. Fasting also prevented an acute post-chemotherapy rise in peripheral blood mononuclear cell DNA damage.
de Groot S, Vreeswijk MP, Welters MJ, et al. BMC Cancer, 2015. PMID 26438237
2015 / Phase 3 double-blind randomized controlled trial
In a phase 3 trial, 386 high-risk participants were randomized to receive 500 mg of nicotinamide twice daily or placebo for 12 months, followed by a 6-month postintervention period. At 12 months, the rate of new nonmelanoma skin cancers was 23% lower in the nicotinamide group compared to placebo (95% CI, 4 to 38; P=0.02). Rates were 20% lower for basal-cell carcinomas (P=0.12) and 30% lower for squamous-cell carcinomas (P=0.05). Actinic keratoses counts were significantly lower in the nicotinamide group at 3, 6, 9, and 12 months, but benefits were not sustained after discontinuation.
Chen AC, Martin AJ, Choy B, et al. N Engl J Med, 2015. PMID 26488693
2015 / Randomized controlled trial
A double-blind trial randomized 56 breast cancer patients receiving doxorubicin into groups consuming 100-160 g/day or 30-40 g/day of fresh yellow onion for eight weeks. Participants consuming the higher amount of onion showed significant reductions in carcinoembryonic antigen, cancer antigen-125, and alkaline phosphatase levels compared to the low-onion group (P < 0.05).
Jafarpour-Sadegh F, Montazeri V, Adili A, et al. Asian Pac J Cancer Prev, 2015. PMID 26625755
2014 / Repeated-measures experimental trial
Sixteen healthy cyclists completed three 30-minute cycling bouts at -5%, +5%, and +15% of lactate threshold to assess NK-cell trafficking and cytotoxicity. Exercise evoked a stepwise redeployment of NK-cells based on differentiation status (highly differentiated > medium-differentiated > low-differentiated) across all intensities. Additionally, NK-cell cytotoxic activity per cell increased ~1.6-fold against U266 and 221 AEH targets 1 hour post-exercise, corresponding to shifts in CD158b and NKG2C expression.
Bigley AB, Rezvani K, Chew C, et al. Brain Behav Immun, 2014. PMID 24200514
2014 / Randomized double-blind placebo-controlled trial
Ninety-eight women with persistent oncogenic HPV and cervical intraepithelial neoplasia received either daily Polyphenon E or placebo for four months. Complete clearance occurred in 17.1% (7 women) of the intervention group and 14.6% (6 women) receiving placebo, showing no significant difference between treatments. Furthermore, disease progression was observed in 14.6% of women taking the extract compared to 7.7% of those given placebo.
Garcia FA, Cornelison T, Nuño T, et al. Gynecol Oncol, 2014. PMID 24388920
2014 / Randomized controlled trial
A randomized trial assigned 130 breast cancer patients undergoing mastectomy to receive 10 mg oral beta-glucan capsules twice daily or placebo for 10 days. Beta-glucan significantly lowered daily drainage volumes between days 2 and 8 and shortened mean drain removal time to 7.16 days compared to 8.59 days with placebo (p < 0.001). Interleukin-6 and tumor necrosis factor-alpha levels on days 1 and 2 were also significantly lower with beta-glucan (p < 0.001).
Yenidogan E, Akgul GG, Gulcelik MA, et al. Adv Ther, 2014. PMID 24421054
2014 / Case-cohort study within a randomized trial
In a case-cohort analysis of the SELECT trial, researchers evaluated whether baseline toenail selenium modified the effects of selenium and vitamin E on prostate cancer (PCa) risk. Selenium supplementation did not affect risk in men with low baseline selenium (<60th percentile) but increased high-grade PCa risk by 91% (P = .007) in men with higher baseline selenium. Vitamin E alone had no effect in men with high baseline selenium (≥40th percentile) but increased risks of total (63%, P = .02) and high-grade PCa (111%, P = .008) among men with lower baseline selenium status.
Kristal AR, Darke AK, Morris JS, et al. J Natl Cancer Inst, 2014. PMID 24563519
2014 / Randomized controlled trial
A randomized trial tested a capsule containing pomegranate, green tea, broccoli, and turmeric versus placebo for 6 months in 199 men with localized prostate cancer. The median increase in prostate-specific antigen was significantly lower in the supplement group at 14.7% (95% CI, 3.4-36.7%) compared to 78.5% in the placebo group (95% CI, 48.1-115.5%; P = 0.0008). Significantly fewer supplemented participants chose to exit surveillance (8.2% vs. 27.7%, P = 0.014).
Thomas R, Williams M, Sharma H, et al. Prostate Cancer Prostatic Dis, 2014. PMID 24614693
2014 / Preclinical animal model with preliminary human clinical data
Researchers investigated the effects of prolonged fasting on hematopoietic stem cell protection and regeneration in mice, supplemented by preliminary data from fasting patients. Prolonged fasting lowered circulating IGF-1 levels and PKA activity, promoting stress resistance, self-renewal, and lineage-balanced regeneration in long-term hematopoietic stem cells. Multiple fasting cycles abated chemotherapy-induced immunosuppression and mortality and reversed age-dependent myeloid bias in mice, aligning with preliminary findings indicating lymphocyte protection against chemotoxicity in fasting patients. The proregenerative effects were reproduced by IGF-1 or PKA deficiencies and blunted by exogenous IGF-1.
Cheng CW, Adams GB, Perin L, et al. Cell Stem Cell, 2014. PMID 24905167
2014 / Randomized controlled trial
In a 12-week randomized trial of 291 adults in China, drinking a daily broccoli sprout beverage significantly increased urinary excretion of glutathione conjugates of benzene by 61% and acrolein by 23% compared with placebo (P <= 0.01). Excretion of crotonaldehyde conjugates remained unchanged. Urinary sulforaphane metabolites showed that bioavailability was sustained throughout the 12-week daily dosing regimen.
Egner PA, Chen JG, Zarth AT, et al. Cancer Prev Res (Phila), 2014. PMID 24913818
2013 / Randomized, double-blind clinical trial
In a randomized, double-blind clinical trial, patients were assigned to receive Mentha spicata, Mentha × piperita, placebo, or a control condition continuing their previous antiemetic regimen (50 courses analysed per group). Both mint essential oil groups experienced a significant reduction in the intensity and number of emetic events in the first 24 hours compared with the control (p < 0.05). No adverse effects were reported, and the cost of treatment was also reduced when essential oils were used.
Tayarani-Najaran Z, Talasaz-Firoozi E, Nasiri R, et al. Ecancermedicalscience, 2013. PMID 23390455
2013 / Phase I clinical trial
Sixteen pancreatic or biliary tract cancer patients who had failed standard chemotherapy received daily oral Theracurmin at either 200 mg (n = 10) or 400 mg (n = 6) with gemcitabine-based chemotherapy. Median peak plasma curcumin concentrations reached 324 ng/mL at the lower dose and 440 ng/mL at the higher dose. No unexpected adverse events occurred, and three individuals safely continued Theracurmin for more than 9 months.
Kanai M, Otsuka Y, Otsuka K, et al. Cancer Chemother Pharmacol, 2013. PMID 23543271
2013 / Open-label clinical trial
Forty-three women with newly diagnosed operable breast cancer took 2 grams of limonene daily for 2 to 6 weeks before surgical resection. Limonene preferentially concentrated in breast tissue, reaching a mean level of 41.3 µg/g, and led to a 22% reduction in tumor cyclin D1 expression (p = 0.002). Circulating IGF-I increased slightly, while tissue Ki67, cleaved caspase-3, leptin, adiponectin, and IL-6 showed no significant alterations.
Miller JA, Lang JE, Ley M, et al. Cancer Prev Res (Phila), 2013. PMID 23554130
2013 / Phase I dose-escalation clinical trial
Five cohorts of three patients with advanced solid tumors received intravenous ascorbic acid at 1 g/min for 4 consecutive days per week for 4 weeks, starting at 30 g/m² with 20 g/m² dose escalations. Ascorbic acid was eliminated by first-order kinetics with a half-life of 2.0 ± 0.6 h and clearance of 21 ± 5 dL/h m². Cmax and AUC increased with dose up to 70 g/m² (reaching 49 mM and 220 h mM, respectively). All doses were well tolerated, but no patient demonstrated an objective antitumor response.
Stephenson CM, Levin RD, Spector T, et al. Cancer Chemother Pharmacol, 2013. PMID 23670640
2013 / Single-blind placebo-controlled crossover trial
In a 3-month trial, 15 postmenopausal women took 5 g daily of placebo for 4 weeks, seaweed (Undaria) for 4 weeks, and placebo for another 4 weeks. Urinary creatinine-standardized uPAR decreased significantly during seaweed intake (placebo 1: 1.5 [95% CI, 0.9-2.1]; seaweed: 0.9 [95% CI, 0.6-1.1]; placebo 2: 1.7 [95% CI, 1.2-2.2]; p = 0.01). A urinary protein (m/z 9,776) showed a similar reversible decrease, while a serum protein (m/z 8,928) reversibly increased.
Teas J, Vena S, Cone DL, et al. J Appl Phycol, 2013. PMID 23678231
2013 / Randomized controlled trial
In the Women's Health Initiative Dietary Modification trial, 48,835 postmenopausal women were randomized to a low-fat dietary pattern intervention (n = 19,541) or a comparison group (n = 29,294) with a target of decreasing fat to 20% or less of calories and increasing vegetables, fruits, and grains. Over 8.1 years of follow-up, the intervention did not significantly affect overall incidence of NMSC (HR 0.98; 95% CI, 0.92-1.04) or melanoma (HR 1.04; 95% CI, 0.82-1.32). However, a significant interaction was observed between baseline fat intake and group assignment for melanoma risk (Pinteraction = 0.006), showing increased risk with the intervention among women with higher baseline fat intake (HR 1.48; 95% CI, 1.06-2.07) and a trend toward reduced risk among those with lower baseline fat intake (HR 0.72; 95% CI, 0.50-1.02).
Gamba CS, Stefanick ML, Shikany JM, et al. Cancer Epidemiol Biomarkers Prev, 2013. PMID 23697610
2013 / Randomized controlled trial
A multicenter trial randomized 177 men at high risk of prostate cancer recurrence to receive daily powder with 20 g of soy protein isolate or calcium caseinate for up to 2 years. The trial was halted early for futility after an interim analysis of 159 evaluable men. Biochemical recurrence developed in 27.2% of the soy group and 29.5% of the placebo group, showing no significant difference (hazard ratio 0.96; 95% CI, 0.53-1.72; P = .89).
Bosland MC, Kato I, Zeleniuch-Jacquotte A, et al. JAMA, 2013. PMID 23839751